Epicutaneous immunotherapy induces gastrointestinal LAP+ regulatory T cells and prevents food-induced anaphylaxis

Journal of Allergy and Clinical Immunology

Volumn 139, Issue 1, 2017, Pages 189-201.e4

  Tordesillas, Leticia ^a   Mondoulet, Lucie ^b   Blazquez, Ana Belen ^a   Benhamou, Pierre Henri ^b   Sampson, Hugh A ^a   Berin, M Cecilia ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DBV TECHNOLOGIES   (France)

Author keywords

Epicutaneous immunotherapy; food allergy; mast cells; oral immunotherapy; regulatory T cells

Indexed keywords

ADJUVANT; ANTIGEN; FOOD ALLERGEN; LATENCY ASSOCIATED PEPTIDE; OVALBUMIN; PEANUT EXTRACT; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; ALLERGEN; CHOLERA TOXIN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; IMMUNOGLOBULIN G; PEPTIDE;

ADOPTIVE TRANSFER; ANAPHYLAXIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DRUG MEGADOSE; EPICUTANEOUS IMMUNOTHERAPY; FLOW CYTOMETRY; FOOD ALLERGY; GASTROINTESTINAL TRACT; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; MAST CELL; MOUSE; NONHUMAN; ORAL IMMUNOTHERAPY; PEANUT ALLERGY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TISSUE SPECIFICITY; TRANSDERMAL PATCH; TRANSGENICS; ANIMAL; ARACHIS; BAGG ALBINO MOUSE; BLOOD; C3H MOUSE; CUTANEOUS DRUG ADMINISTRATION; DESENSITIZATION; FOOD HYPERSENSITIVITY; IMMUNOLOGY; PROCEDURES;

ADMINISTRATION, CUTANEOUS; ALLERGENS; ANAPHYLAXIS; ANIMALS; ARACHIS; CHOLERA TOXIN; DESENSITIZATION, IMMUNOLOGIC; FOOD HYPERSENSITIVITY; FORKHEAD TRANSCRIPTION FACTORS; IMMUNOGLOBULIN G; MICE, INBRED BALB C; MICE, INBRED C3H; OVALBUMIN; PEPTIDES; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA;

EID: 85002567316     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.03.057     Document Type: Article

References (61)

1. 1 Sicherer, S.H., Epidemiology of food allergy. J Allergy Clin Immunol 127 (2011), 594–602.
2. 2 Fleischer, D.M., Perry, T.T., Atkins, D., Wood, R.A., Burks, A.W., Jones, S.M., et al. Allergic reactions to foods in preschool-aged children in a prospective observational food allergy study. Pediatrics 130 (2012), e25–e32.
3. 3 Nelson, H.S., Lahr, J., Rule, R., Bock, A., Leung, D., Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract. J Allergy Clin Immunol 99 (1997), 744–751.
4. 4 Burks, A.W., Jones, S.M., Wood, R.A., Fleischer, D.M., Sicherer, S.H., Lindblad, R.W., et al. Oral immunotherapy for treatment of egg allergy in children. N Engl J Med 367 (2012), 233–243.
5. 5 Varshney, P., Jones, S.M., Scurlock, A.M., Perry, T.T., Kemper, A., Steele, P., et al. A randomized controlled study of peanut oral immunotherapy: clinical desensitization and modulation of the allergic response. J Allergy Clin Immunol 127 (2011), 654–660.
6. 6 Keet, C.A., Seopaul, S., Knorr, S., Narisety, S., Skripak, J., Wood, R.A., Long-term follow-up of oral immunotherapy for cow's milk allergy. J Allergy Clin Immunol 132 (2013), 737–739.e6.
7. 7 Syed, A., Garcia, M.A., Lyu, S.C., Bucayu, R., Kohli, A., Ishida, S., et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol 133 (2014), 500–510.
8. 8 Vickery, B.P., Scurlock, A.M., Kulis, M., Steele, P.H., Kamilaris, J., Berglund, J.P., et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol 133 (2014), 468–475.
9. + regulatory T cells in the lamina propria. Immunity 34 (2011), 237–246.
10. 10 Mucida, D., Kutchukhidze, N., Erazo, A., Russo, M., Lafaille, J.J., Curotto de Lafaille, M.A., Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest 115 (2005), 1923–1933.
11. 11 Fukaura, H., Kent, S.C., Pietrusewicz, M.J., Khoury, S.J., Weiner, H.L., Hafler, D.A., Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest 98 (1996), 70–77.
12. 12 Trentham, D.E., Dynesius-Trentham, R.A., Orav, E.J., Combitchi, D., Lorenzo, C., Sewell, K.L., et al. Effects of oral administration of type II collagen on rheumatoid arthritis. Science 261 (1993), 1727–1730.
13. 13 Chaillous, L., Lefevre, H., Thivolet, C., Boitard, C., Lahlou, N., Atlan-Gepner, C., et al. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabete Insuline Orale Group. Lancet 356 (2000), 545–549.
14. 14 Neurath, M.F., Fuss, I., Kelsall, B.L., Presky, D.H., Waegell, W., Strober, W., Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 183 (1996), 2605–2616.
15. 15 Leonard, S.A., Martos, G., Wang, W., Nowak-Wegrzyn, A., Berin, M.C., Oral immunotherapy induces local protective mechanisms in the gastrointestinal mucosa. J Allergy Clin Immunol 129 (2012), 1579–1587.e1.
16. 16 Burton, O.T., Noval Rivas, M., Zhou, J.S., Logsdon, S.L., Darling, A.R., Koleoglou, K.J., et al. Immunoglobulin E signal inhibition during allergen ingestion leads to reversal of established food allergy and induction of regulatory T cells. Immunity, 41, 2014, 14151.
17. 17 Mondoulet, L., Dioszeghy, V., Ligouis, M., Dhelft, V., Dupont, C., Benhamou, P.H., Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. Clin Exp Allergy 40 (2010), 659–667.
18. 18 Mondoulet, L., Dioszeghy, V., Vanoirbeek, J.A., Nemery, B., Dupont, C., Benhamou, P.H., Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. Int Arch Allergy Immunol 154 (2011), 299–309.
19. 19 Mondoulet, L., Dioszeghy, V., Larcher, T., Ligouis, M., Dhelft, V., Puteaux, E., et al. Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. PLoS One, 7, 2012, e31967.
20. 20 Dioszeghy, V., Mondoulet, L., Dhelft, V., Ligouis, M., Puteaux, E., Benhamou, P.H., et al. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. J Immunol 186 (2011), 5629–5637.
21. 21 Dioszeghy, V., Mondoulet, L., Dhelft, V., Ligouis, M., Puteaux, E., Dupont, C., et al. The regulatory T cells induction by epicutaneous immunotherapy is sustained and mediates long-term protection from eosinophilic disorders in peanut-sensitized mice. Clin Exp Allergy 44 (2014), 867–881.
22. 22 Soler, D., Humphreys, T.L., Spinola, S.M., Campbell, J.J., CCR4 versus CCR10 in human cutaneous TH lymphocyte trafficking. Blood 101 (2003), 1677–1682.
23. 23 Ito, T., Carson, W.F.T., Cavassani, K.A., Connett, J.M., Kunkel, S.L., CCR6 as a mediator of immunity in the lung and gut. Exp Cell Res 317 (2011), 613–619.
24. 24 Zabel, B.A., Agace, W.W., Campbell, J.J., Heath, H.M., Parent, D., Roberts, A.I., et al. Human G protein-coupled receptor GPR-9-6/CC chemokine receptor 9 is selectively expressed on intestinal homing T lymphocytes, mucosal lymphocytes, and thymocytes and is required for thymus-expressed chemokine-mediated chemotaxis. J Exp Med 190 (1999), 1241–1256.
25. 25 Berlin, C., Berg, E.L., Briskin, M.J., Andrew, D.P., Kilshaw, P.J., Holzmann, B., et al. Alpha 4 beta 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1. Cell 74 (1993), 185–195.
26. 26 Pabst, O., Mowat, A.M., Oral tolerance to food protein. Mucosal Immunol 5 (2012), 232–239.
27. 27 Akdis, C.A., Akdis, M., Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 127 (2011), 18–27 quiz 8-9.
28. 28 Berin, M.C., Mayer, L., Can we produce true tolerance in patients with food allergy?. J Allergy Clin Immunol 131 (2013), 14–22.
29. 29 Jawdat, D.M., Albert, E.J., Rowden, G., Haidl, I.D., Marshall, J.S., IgE-mediated mast cell activation induces Langerhans cell migration in vivo. J Immunol 173 (2004), 5275–5282.
30. 30 McLachlan, J.B., Shelburne, C.P., Hart, J.P., Pizzo, S.V., Goyal, R., Brooking-Dixon, R., et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 14 (2008), 536–541.
31. 31 Chen, Y., Kuchroo, V.K., Inobe, J., Hafler, D.A., Weiner, H.L., Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265 (1994), 1237–1240.
32. 32 Chen, M.L., Yan, B.S., Bando, Y., Kuchroo, V.K., Weiner, H.L., Latency-associated peptide identifies a novel CD4+CD25+ regulatory T cell subset with TGFbeta-mediated function and enhanced suppression of experimental autoimmune encephalomyelitis. J Immunol 180 (2008), 7327–7337.
33. 33 Ishikawa, H., Ochi, H., Chen, M.L., Frenkel, D., Maron, R., Weiner, H.L., Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes 56 (2007), 2103–2109.
34. 34 Ochi, H., Abraham, M., Ishikawa, H., Frenkel, D., Yang, K., Basso, A.S., et al. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25− LAP+ T cells. Nat Med 12 (2006), 627–635.
35. 35 Oida, T., Zhang, X., Goto, M., Hachimura, S., Totsuka, M., Kaminogawa, S., et al. CD4+CD25− T cells that express latency-associated peptide on the surface suppress CD4+CD45RBhigh-induced colitis by a TGF-beta-dependent mechanism. J Immunol 170 (2003), 2516–2522.
36. 36 Wu, H.Y., Quintana, F.J., Weiner, H.L., Nasal anti-CD3 antibody ameliorates lupus by inducing an IL-10-secreting CD4+ CD25− LAP+ regulatory T cell and is associated with down-regulation of IL-17+ CD4+ ICOS+ CXCR5+ follicular helper T cells. J Immunol 181 (2008), 6038–6050.
37. 37 Duan, W., So, T., Mehta, A.K., Choi, H., Croft, M., Inducible CD4+LAP+Foxp3− regulatory T cells suppress allergic inflammation. J Immunol 187 (2011), 6499–6507.
38. 38 Gandhi, R., Farez, M.F., Wang, Y., Kozoriz, D., Quintana, F.J., Weiner, H.L., Cutting edge: human latency-associated peptide+ T cells: a novel regulatory T cell subset. J Immunol 184 (2010), 4620–4624.
39. 39 Mahalingam, J., Lin, Y.C., Chiang, J.M., Su, P.J., Fang, J.H., Chu, Y.Y., et al. LAP+CD4+ T cells are suppressors accumulated in the tumor sites and associated with the progression of colorectal cancer. Clin Cancer Res 18 (2012), 5224–5233.
40. 40 Scurr, M., Ladell, K., Besneux, M., Christian, A., Hockey, T., Smart, K., et al. Highly prevalent colorectal cancer-infiltrating LAP(+) Foxp3(−) T cells exhibit more potent immunosuppressive activity than Foxp3(+) regulatory T cells. Mucosal Immunol 7 (2014), 428–439.
41. 41 Perez-Machado, M.A., Ashwood, P., Thomson, M.A., Latcham, F., Sim, R., Walker-Smith, J.A., et al. Reduced transforming growth factor-beta1-producing T cells in the duodenal mucosa of children with food allergy. Eur J Immunol 33 (2003), 2307–2315.
42. 42 Beyer, K., Castro, R., Birnbaum, A., Benkov, K., Pittman, N., Sampson, H.A., Human milk-specific mucosal lymphocytes of the gastrointestinal tract display a TH2 cytokine profile. J Allergy Clin Immunol 109 (2002), 707–713.
43. 43 Han, Y., Guo, Q., Zhang, M., Chen, Z., Cao, X., CD69+ CD4+ CD25− T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1. J Immunol 182 (2009), 111–120.
44. 44 Boswell, S., Pathan, A.A., Pereira, S.P., Williams, R., Behboudi, S., Induction of CD152 (CTLA-4) and LAP (TGF-beta1) in human Foxp3− CD4+ CD25− T cells modulates TLR-4 induced TNF-alpha production. Immunobiology 218 (2013), 427–434.
45. 45 Zheng, S.G., Gray, J.D., Ohtsuka, K., Yamagiwa, S., Horwitz, D.A., Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25− precursors. J Immunol 169 (2002), 4183–4189.
46. 46 Mora, J.R., Bono, M.R., Manjunath, N., Weninger, W., Cavanagh, L.L., Rosemblatt, M., et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424 (2003), 88–93.
47. 47 Stagg, A.J., Kamm, M.A., Knight, S.C., Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 32 (2002), 1445–1454.
48. 48 Campbell, D.J., Butcher, E.C., Rapid acquisition of tissue-specific homing phenotypes by CD4(+) T cells activated in cutaneous or mucosal lymphoid tissues. J Exp Med 195 (2002), 135–141.
49. 49 Dudda, J.C., Simon, J.C., Martin, S., Dendritic cell immunization route determines CD8+ T cell trafficking to inflamed skin: role for tissue microenvironment and dendritic cells in establishment of T cell-homing subsets. J Immunol 172 (2004), 857–863.
50. 50 Ciabattini, A., Pettini, E., Fiorino, F., Prota, G., Pozzi, G., Medaglini, D., Distribution of primed T cells and antigen-loaded antigen presenting cells following intranasal immunization in mice. PLoS One, 6, 2011, e19346.
51. 51 Ruane, D., Brane, L., Reis, B.S., Cheong, C., Poles, J., Do, Y., et al. Lung dendritic cells induce migration of protective T cells to the gastrointestinal tract. J Exp Med 210 (2013), 1871–1888.
52. 52 Kashyap, M., Thornton, A.M., Norton, S.K., Barnstein, B., Macey, M., Brenzovich, J., et al. Cutting edge: CD4 T cell-mast cell interactions alter IgE receptor expression and signaling. J Immunol 180 (2008), 2039–2043.
53. 53 Ganeshan, K., Bryce, P.J., Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF-beta. J Immunol 188 (2012), 594–603.
54. 54 Gri, G., Piconese, S., Frossi, B., Manfroi, V., Merluzzi, S., Tripodo, C., et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 29 (2008), 771–781.
55. 55 Gomez, G., Ramirez, C.D., Rivera, J., Patel, M., Norozian, F., Wright, H.V., et al. TGF-beta 1 inhibits mast cell Fc epsilon RI expression. J Immunol 174 (2005), 5987–5993.
56. 56 Zhao, W., Gomez, G., Yu, S.H., Ryan, J.J., Schwartz, L.B., TGF-beta1 attenuates mediator release and de novo Kit expression by human skin mast cells through a Smad-dependent pathway. J Immunol 181 (2008), 7263–7272.
57. 57 Carrier, Y., Yuan, J., Kuchroo, V.K., Weiner, H.L., Th3 cells in peripheral tolerance, I: induction of Foxp3-positive regulatory T cells by Th3 cells derived from TGF-beta T cell-transgenic mice. J Immunol 178 (2007), 179–185.
58. Blazquez, A.B., Mayer, L., Berin, M.C., Thymic stromal lymphopoietin is required for gastrointestinal allergy but not oral tolerance. Gastroenterology 139 (2010), 1301–1309.
59. Leonard, S.A., Martos, G., Wang, W., Nowak-Wegrzyn, A., Berin, M.C., Oral immunotherapy induces local protective mechanisms in the gastrointestinal mucosa. J Allergy Clin Immunol 129 (2012), 1579–1587.e1.
60. Ekoff, M., Strasser, A., Nilsson, G., FcepsilonRI aggregation promotes survival of connective tissue-like mast cells but not mucosal-like mast cells. J Immunol 178 (2007), 4177–4183.
61. Kuehn, H.S., Radinger, M., Gilfillan, A.M., Measuring mast cell mediator release. Curr Protoc Immunol, 2010 Chapter 7:Unit7.38.